HLDF-6 peptides exhibit neuroprotective effects in the experimental model of preclinical Parkinson's disease

[1]  M. Ugrumov,et al.  A Mouse Model of Nigrostriatal Dopaminergic Axonal Degeneration As a Tool for Testing Neuroprotectors , 2021, Acta naturae.

[2]  S. Zozulya,et al.  Neurotropic peptide HLDF-6-amide reduces age-related decline in sexual activity in old male rats , 2021, Experimental Gerontology.

[3]  V. Lipkin,et al.  Influence of Subchronic Administration of the HLDF-6 Peptide on an Efficacy of the Exploratory Behavior of Inbred Mice of the Balb/c and C57Bl/6 Strains , 2021 .

[4]  Stephen Nuara,et al.  Effect of the mGlu2 positive allosteric modulator CBiPES on dyskinesia, psychosis-like behaviours and parkinsonism in the MPTP-lesioned marmoset , 2021, Journal of Neural Transmission.

[5]  N. Myasoedov,et al.  Investigation of the Hydrolytic Stability of the HLDF-6-AA Antitumor Peptide by the Method of Accelerated Aging , 2020, Russian Journal of Bioorganic Chemistry.

[6]  M. Husain,et al.  Dopamine and reward hypersensitivity in Parkinson’s disease with impulse control disorder , 2020, Brain : a journal of neurology.

[7]  A. Maggi,et al.  The role of sex and sex Hormones in Neurodegenerative Diseases. , 2020, Endocrine reviews.

[8]  D. S. Lazarev,et al.  The Administration of Semax and HLDF-6 Peptides to Rats Regulates Protein Synthesis Rhythm in Hepatocytes and Corrects Senescent Disturbances , 2020, Russian Journal of Developmental Biology.

[9]  S. Rai,et al.  Advancement in the modelling and therapeutics of Parkinson’s disease , 2020, Journal of Chemical Neuroanatomy.

[10]  D. S. Lazarev,et al.  Neuroprotective Peptides Regulate Protein-Synthesis Kinetics in Hepatocytes of Different Age Rats , 2019, Russian Journal of Developmental Biology.

[11]  S. Rai,et al.  Anti-inflammatory Activity of Ursolic Acid in MPTP-Induced Parkinsonian Mouse Model , 2019, Neurotoxicity Research.

[12]  S. Rai,et al.  Effect of Chlorogenic Acid Supplementation in MPTP-Intoxicated Mouse , 2018, Front. Pharmacol..

[13]  A. Bazyan,et al.  MPTP Mouse Model of Preclinical and Clinical Parkinson’s Disease as an Instrument for Translational Medicine , 2018, Molecular Neurobiology.

[14]  S. Rai,et al.  Mucuna pruriens Protects against MPTP Intoxicated Neuroinflammation in Parkinson’s Disease through NF-κB/pAKT Signaling Pathways , 2017, Front. Aging Neurosci..

[15]  Zishan Wang,et al.  Dynamic Changes in the Nigrostriatal Pathway in the MPTP Mouse Model of Parkinson's Disease , 2017, Parkinson's disease.

[16]  Paolo Barone,et al.  The relevance of gender in Parkinson’s disease: a review , 2017, Journal of Neurology.

[17]  V. Lipkin,et al.  Anxiolytic activity of the neuroprotective peptide HLDF-6 and its effects on brain neurotransmitter systems in BALB/c and C57BL/6 mice , 2016, Journal of psychopharmacology.

[18]  Stefano Tamburin,et al.  Pathophysiology of Motor Dysfunction in Parkinson's Disease as the Rationale for Drug Treatment and Rehabilitation , 2016, Parkinson's disease.

[19]  A. Maggi,et al.  Estrogens, Neuroinflammation, and Neurodegeneration. , 2016, Endocrine reviews.

[20]  V. Lipkin,et al.  Comparative study of the neuroprotective and nootropic activities of the carboxylate and amide forms of the HLDF-6 peptide in animal models of Alzheimer’s disease , 2016, Journal of psychopharmacology.

[21]  E. Bocharov,et al.  The qualitative analysis of the amide of the HLDF-6 peptide and its metabolites in tissues of laboratory animals with the use of tritium-labeled and deuterium-labeled derivatives , 2015, Russian Journal of Bioorganic Chemistry.

[22]  M. Morissette,et al.  The 5α-reductase inhibitor Dutasteride but not Finasteride protects dopamine neurons in the MPTP mouse model of Parkinson's disease , 2015, Neuropharmacology.

[23]  A. Lang,et al.  Parkinson's disease , 2015, The Lancet.

[24]  M. Vital,et al.  Neuroinflammation in the pathophysiology of Parkinson's disease and therapeutic evidence of anti-inflammatory drugs. , 2015, Arquivos de neuro-psiquiatria.

[25]  G. Gillies,et al.  Sex differences in Parkinson’s disease , 2014, Frontiers in Neuroendocrinology.

[26]  Danilenko Ed,et al.  МОДУЛЯЦИЯ ПЕПТИДОМ HLDF6 ФУНКЦИОНАЛЬНОЙ АКТИВНОСТИ МАКРОФАГОВ НА ФОНЕ ВВЕДЕНИЯ АГОНИСТОВ ОПИАТНЫХ РЕЦЕПТОРОВ , 2014 .

[27]  Claire Williams,et al.  Neuroprotective and symptomatic effects of targeting group III mGlu receptors in neurodegenerative disease , 2014, Journal of neurochemistry.

[28]  K. Rayevsky,et al.  Modeling of presymptomatic and symptomatic stages of parkinsonism in mice , 2011, Neuroscience.

[29]  E. Kozina,et al.  Dopamine release in the substantia nigra and striatum at presymptomatic and early symptomatic stages in parkinsonian mice , 2011, Neurochemical Journal.

[30]  T. Di Paolo,et al.  Steroids‐Dopamine Interactions in the Pathophysiology and Treatment of CNS Disorders , 2010, CNS neuroscience & therapeutics.

[31]  Ji Hyun Choi,et al.  Vertical grid test and modified horizontal grid test are sensitive methods for evaluating motor dysfunctions in the MPTP mouse model of Parkinson's disease , 2010, Brain Research.

[32]  Z. Storozheva,et al.  Postischemic administration of HLDF-6 peptide ameliorates cognitive dysfunction and brain damage induced by chronic cerebral Ischemia in rats , 2009, Doklady Biological Sciences.

[33]  P. Gubellini,et al.  Electrophysiological and behavioral evidence that modulation of metabotropic glutamate receptor 4 with a new agonist reverses experimental parkinsonism , 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[34]  D. Dluzen,et al.  Neuroprotective actions of sex steroids in Parkinson’s disease , 2009, Frontiers in Neuroendocrinology.

[35]  A. Członkowska,et al.  Age- and sex-differences in the nitric oxide synthase expression and dopamine concentration in the murine model of Parkinson's disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine , 2009, Brain Research.

[36]  M. Mena,et al.  Gender differences and estrogen effects in parkin null mice , 2008, Journal of neurochemistry.

[37]  A. Stępień,et al.  Serum interleukin (IL-2, IL-10, IL-6, IL-4), TNFα, and INFγ concentrations are elevated in patients with atypical and idiopathic parkinsonism , 2008, Neuroscience Letters.

[38]  S. Callier,et al.  Estrogen and SERM neuroprotection in animal models of Parkinson's disease , 2008, Molecular and Cellular Endocrinology.

[39]  I. Babichenko,et al.  Neuroprotective effect of the hexapeptide HLDF-6 on rat hippocampal neurons on the in vivo and in vitro models of alzheimer’s disease , 2006, Russian Journal of Bioorganic Chemistry.

[40]  D. Finkelstein,et al.  Estrogen down-regulates glial activation in male mice following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine intoxication , 2006, Brain Research.

[41]  R. Sewell,et al.  Does the human leukaemia differentiation factor fragment HLDF6 improve memory via brain DNA and protein synthesis? , 2005, Journal of psychopharmacology.

[42]  E. Bézard,et al.  Unraveling substantia nigra sequential gene expression in a progressive MPTP-lesioned macaque model of Parkinson's disease , 2005, Neurobiology of Disease.

[43]  D. I. Rzhevsky,et al.  HLDF-6 peptide affects behavioral reactions and organism functions dependent on androgen hormones in normal and castrated male mice , 2005, Regulatory Peptides.

[44]  M. Sawada,et al.  Inflammatory process in Parkinson's disease: role for cytokines. , 2005, Current pharmaceutical design.

[45]  P. Neveu,et al.  Interleukine-1β and interleukine-6 levels in striatum and other brain structures after MPTP treatment: influence of behavioral lateralization , 2005, Journal of Neuroimmunology.

[46]  I. Babichenko,et al.  Different Mechanisms of Protective and Differentiative Activities of Homological Peptides TGENHR and TQVEHR , 2004, Biochemistry (Moscow).

[47]  I. Babichenko,et al.  The Precursor of Differentiation Factor HLDF and Ribosomal Protein RPS21 Have a Common N-Terminal Sequence , 2004, Russian Journal of Bioorganic Chemistry.

[48]  Y. Kitamura,et al.  Disease model: Parkinson's disease. , 2003, Trends in molecular medicine.

[49]  G. Miller,et al.  Grid performance test to measure behavioral impairment in the MPTP-treated-mouse model of parkinsonism , 2003, Journal of Neuroscience Methods.

[50]  H. Braak,et al.  Staging of brain pathology related to sporadic Parkinson’s disease , 2003, Neurobiology of Aging.

[51]  T. Di Paolo,et al.  Neuroprotective properties of 17β‐estradiol, progesterone, and raloxifene in MPTP C57Bl/6 mice , 2001, Synapse.

[52]  F. Nicoletti,et al.  Time-course and dose–response study on the effects of chronic l-DOPA administration on striatal dopamine levels and dopamine transporter following MPTP toxicity , 2000, Brain Research.

[53]  I. Molotkovskaya,et al.  A biologically active fragment of the differentiation factor of the HL-60 line cells: Identification and properties , 2000, Russian Journal of Bioorganic Chemistry.

[54]  A. Ho,et al.  Induction of Interleukin-1 Associated with Compensatory Dopaminergic Sprouting in the Denervated Striatum of Young Mice: Model of Aging and Neurodegenerative Disease , 1998 .

[55]  N. Ogawa,et al.  Pole test is a useful method for evaluating the mouse movement disorder caused by striatal dopamine depletion , 1997, Journal of Neuroscience Methods.

[56]  M. Diksic,et al.  Influence of Fluoxetine on Regional Serotonin Synthesis in the Rat Brain , 1996, Journal of neurochemistry.

[57]  R. Burke,et al.  Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. , 1995, Neurodegeneration : a journal for neurodegenerative disorders, neuroprotection, and neuroregeneration.

[58]  P. Riederer,et al.  Transforming growth factor-β1 levels are elevated in the striatum and in ventricular cerebrospinal fluid in Parkinson's disease , 1995, Neuroscience Letters.

[59]  V. Lipkin,et al.  A new human leukemia cell 8.2 kDa differentiation factor: Isolation and primary structure , 1994, FEBS letters.

[60]  Alexander Storch,et al.  Nonmotor Fluctuations in Parkinson's Disease. , 2017, International review of neurobiology.

[61]  S. Mitchell,et al.  Recent developments in metabotropic glutamate receptors as novel drug targets , 2010, Drug News & Perspectives.